Related Experiment Video

Updated: Jun 10, 2026

Ultrasound-Guided Orthotopic Implantation of Murine Pancreatic Ductal Adenocarcinoma
06:21

Ultrasound-Guided Orthotopic Implantation of Murine Pancreatic Ductal Adenocarcinoma

Published on: November 19, 2019

Targeted inhibition of SRC kinase signaling attenuates pancreatic tumorigenesis

Nagathihalli S Nagaraj1, J Joshua Smith, Frank Revetta

  • 1Department of Surgery, Vanderbilt University School of Medicine, Nashville, TN, USA.

Molecular Cancer Therapeutics
|August 5, 2010
PubMed

Insights

Src kinase inhibition with dasatinib shows promise for pancreatic cancer treatment. Dasatinib effectively inhibits pancreatic ductal adenocarcinoma cell growth and migration, with resistance linked to STAT3 and MAPK signaling pathways.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • Elevated Src expression is linked to malignancy and metastasis in various cancers, including pancreatic ductal adenocarcinoma (PDA).
  • The role of Src kinase in PDA progression and the efficacy of its inhibition require further elucidation.

Purpose of the Study:

  • To investigate the molecular effects of Src kinase inhibition using dasatinib in pancreatic ductal adenocarcinoma (PDA).
  • To identify potential mechanisms of resistance to dasatinib treatment in PDA.

Main Methods:

  • Utilized dasatinib, a multitargeted kinase inhibitor, to target Src family kinases in PDA cell lines and in vivo models.
  • Assessed dasatinib's effects on cell proliferation, migration, invasion, apoptosis, and downstream signaling pathways (Src, FAK, paxillin, AKT, STAT3, ERK, MAPK, cyclin D1).
  • Employed small interfering RNA (siRNA) targeting Src to validate its role in PDA cell behavior.

Main Results:

  • Dasatinib significantly inhibited PDA cell proliferation, migration, invasion, cell cycle progression, and anchorage-independent growth, while promoting apoptosis.
  • Inhibition of Src phosphorylation and downstream signaling pathways, including FAK, paxillin, AKT, STAT3, ERK, MAPK, and cyclin D1, was observed.
  • Membranous Src expression in pancreatic tumors correlated with decreased patient survival, whereas cytoplasmic expression was associated with better outcomes.
  • Dasatinib treatment effectively inhibited tumor growth in vivo.
  • Resistance to dasatinib was associated with incomplete inhibition of STAT3 and MAPK signaling.

Conclusions:

  • Src kinase inhibition with dasatinib demonstrates significant anti-cancer effects in PDA, establishing a rationale for its therapeutic use.
  • Cellular localization of Src (membranous vs. cytoplasmic) is a potential prognostic biomarker in PDA.
  • Understanding resistance mechanisms involving STAT3 and MAPK signaling is crucial for optimizing dasatinib therapy in pancreatic cancer.

More Related Videos

Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies07:29

Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies

Published on: June 20, 2015

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...